Acacia Pharma is a commercial-stage biopharmaceutical company developing and commercialising novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures or chemotherapy. It has two assets: BARHEMSYS (launched for PONV in the US) and in-licensed asset BYFAVO (for PS).
Acacia Pharma is focused on commercialising its two approved hospital-based products in the US. Lead product BARHEMSYS (reformulated amisulpride) was launched in August 2020 after receiving FDA approval with a broad label for the management of post-operative nausea and vomiting (PONV). Under the deal with Cosmo Pharmaceuticals, Acacia was assigned the US licence for Paion’s sedative BYFAVO (remimazolam), which received FDA approval for procedural sedation (PS) in July 2020 and has been designated as a Schedule IV medicine. Acacia launched BYFAVO in January 2020 and continues to build out its US commercial operations. At 30 June 2020, Acacia had net cash of $21.9m. A share placing in August that raised €25m gross plus the €45m combined equity investment and loan facility under the Cosmo deal has enabled Acacia to expand its US commercial infrastructure to support both product launches.
Inadequately treated PONV leads to prolonged stays in post-anaesthesia care unit recovery rooms. Use of BARHEMSYS could reduce patient hospitalisation time and the associated costs. Likewise, BYFAVO can reduce the time required for invasive medical procedures, enabling increased patient throughput for hospitals and surgical centres.